Patents
Sitemap › C12 - Biochemistry; Beer; Spirits; Wine; Vinegar; Microbiology; Enzymology; Mutation or genetic engineering › C12P - Fermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture › C12P 21 - Preparation of peptides or proteins
Patents for C12P 21 - Preparation of peptides or proteins (112,499)
08/2005
08/30/2005US6936437 Solubilizing and recovering genetically engineered troponin produced as inclusion bodies
08/30/2005US6936424 Materials and methods for detection and treatment of breast cancer
08/30/2005US6936422 Staphylococcus culture; genetic engineering
08/30/2005US6936259 For therapy and prophylaxis of bacterial infections
08/30/2005US6936258 Staphylococcus antigen and vaccine
08/30/2005US6936251 Detection using antibodies
08/30/2005US6936248 Methods of inhibiting GPR-9-6 function
08/30/2005CA2294647C Diagnostic assays using soluble endothelial cell protein c/activated protein c receptor
08/30/2005CA2103887C Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
08/30/2005CA1341490C Dna functional group and plasmid coding for hirudine, transformed yeast, preparation process for hirudine, resulting hirudine, and its pharmaceutical use
08/30/2005CA1341489C Family of primate hematopoietic growth factors
08/30/2005CA1341488C Precursor antigens for human retorvirus (hiv-2) envelope glycoproteins, and immunologically related antigens
08/26/2005CA2456595A1 Process for identifying eukariotic tumor cells or bacteria arboring a genomic alteration in at least one part of a gene encoding for a transcription factor
08/25/2005WO2005078449A1 Method and kit for identifying the function of gene product and identifying binding substance
08/25/2005WO2005078116A1 A method of isolating antibacterial peptides and the isolated peptides thereof
08/25/2005WO2005078087A1 Antibody targeting osteoclast-associated protein
08/25/2005WO2005078085A1 Polypeptide having collagen-like structure
08/25/2005WO2005078077A2 Acid alpha-glucosidase and fragments thereof
08/25/2005WO2005077984A1 Process for producing organic compound and antibody for use therein
08/25/2005WO2005077976A2 Coiled-coil domains from c4b-binding protein
08/25/2005WO2005077421A1 A method of preparing polyethylene glycol modified interferon alpha 1b
08/25/2005WO2005077417A1 Inhibition of factor b, the alternative complement pathway and methods related thereto
08/25/2005WO2005077093A2 Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
08/25/2005WO2005077090A2 Improved methods of producing antibody conjugates
08/25/2005WO2005063816A3 Monovalent antibody fragments useful as therapeutics
08/25/2005WO2005033134A3 Secreted protein therapeutics and uses thereof
08/25/2005WO2005030982A3 Coordinated decrease and increase of gene expression of more than one gene using transgenic constructs
08/25/2005WO2004113500A3 B7s1: an immune modulator
08/25/2005US20050188427 Lysyl oxidase-like 1 (LOXL1) and elastogenesis
08/25/2005US20050187380 Method for treating Th2-mediated disease
08/25/2005US20050187379 Secreted and transmembrane polypeptides and nucleic acids encoding the same
08/25/2005US20050187378 nucleotide sequences encoding oligopeptide sequences which can render fusion partner proteins environmental stress resistant by binding thereto while conserving their intrinsic properties; recombinant vectors, and cells transformed by them
08/25/2005US20050187179 treatment of tumors which have increased Notch expression; administration of either Notch antisense oligonucleotides or monoclonal antibodies directed to Notch along with cell differentiating agent
08/25/2005US20050187177 chimeric gene construct composed of a COX-2 promoter operably linked to at least one apoptosis-inducing gene that can cause selectively induced apoptosis in a population of diseased cells; entire classes of cells can be treated with one transfection
08/25/2005US20050187160 soluble proteins containing free cysteine residues and having increased efficiency
08/25/2005US20050187155 For systematical, local or topical inhibition of metalloproteinases
08/25/2005US20050186666 Protein expression systems
08/25/2005US20050186665 Expressed ligand - vascular intercellular signaling molecule
08/25/2005US20050186664 Albumin fusion proteins
08/25/2005US20050186663 Cystine-knot fold protein
08/25/2005US20050186660 Using calcitonin precursor protein as diagnostic tool in detection of cancer and sepsis
08/25/2005US20050186659 Methods for protein purification
08/25/2005US20050186657 Glycoprotein synthesis
08/25/2005US20050186656 Glycoprotein synthesis
08/25/2005US20050186655 Preparation containing cell extracts for cell-free protein synthesis and means for synthesizing protein using the preparation
08/25/2005US20050186654 Contacting L-alanine methyl ester as carboxy component and L-glutamine as amine component to an enzyme (E. coli JM 109) which catalyzes hydrolysis of amino acid ester to form a dipeptide; enzyme derived from a microorganism belonging to the genus Acetobacter
08/25/2005US20050186634 Peptides for use in culture media
08/25/2005US20050186628 Dorsalin-1 polypeptide and uses thereof
08/25/2005US20050186626 Chicken leukemia inhibitory factor (LIF) and gene thereof
08/25/2005US20050186621 Using host cells to propagate preferential viral proteins for use in generating vaccines aganist microorganismal infection
08/25/2005US20050186620 Polypeptide fusion comprising three nonoverlapping domains for use as tool in identifying modulator for enhancing immune response
08/25/2005US20050186618 ADAM gene having a novel base sequence; an ADAM protein encoded by it has the protease activity and is involved in degradation of an extracellular matrix; recombinant vector comprising the DNA; recombinant host cell
08/25/2005US20050186617 Transgenic cell comprising vitamin d3 receptor for use as gene expression diagnostic tool which monitor conversion of ligand precursors into ligands
08/25/2005US20050186575 Corona-virus-like particles comprising functionally deleted genomes
08/25/2005US20050186568 Enzymatic polypeptides for use as drug screening tools; pharmacological toxicity
08/25/2005US20050186564 Production of proteins
08/25/2005US20050186562 Method for early detection during the clinical phase of the infection, reliable, rapid, inexpensive, making it possible to adapt the medical care in time
08/25/2005US20050186286 By treating separated dermis with a protease and a surfactant simultaneously, it is possible to decellularize dermis substantially completely without greatly denaturing intrinsic collagen structure of dermis while attenuating residual basement membrane components; use in burn treatment
08/25/2005US20050186266 Chlamydia antigens and corresponding DNA fragments and uses thereof
08/25/2005US20050186220 derived from canine distemper virus; vaccines for inducing immune response
08/25/2005US20050186214 Antiproliferative agents; chimeric molecules to direct cytotoxins, imaging reagents, and drugs; cells, kits
08/25/2005US20050186211 Use of mda-5 as an antiviral and antiproliferative agent
08/25/2005US20050186209 Protein between 30% but less than 100% identical to a human protein, contains a mutation characteristic of an analogous non-human protein; is capable of raising antibodies in human, antibodies bind to both the human protein and the polypeptide
08/25/2005US20050186205 Administering unlabelled anti-CD20 antibody that binds to the CD20 antigen present on lymphoma cells; a second treatment of cyclophosphamide, doxorubicin, vincristine or prednisone
08/25/2005US20050186203 Isolated antibody bound to human insulin-like growth factor-I receptor, identification of its CDRs (complementarity-determining regions), inhibiting the tyrosine kinase activity of the IGF-IR receptor
08/25/2005US20050186201 Peptides immunoreactive with autoantibodies from patients suffering from rheumatoid arthritis
08/25/2005US20050186187 Altering the expression levels of a protein; modulating the activity of secretory leukocyte protease inhibitor (SLPI), CD53, or Transferrin-1 in a cell and culturing the cells
08/25/2005US20050186180 Recombinant virus encoding an antigen of a disease state; second recombinant virus encoding an immunostimulatory molecule with an exogenous immunostimulatory molecule, chemotherapeutic drug, antibiotic, antiviral drug or antifungal drug.
08/25/2005CA2561531A1 Inhibition of factor b, the alternative complement pathway and methods related thereto
08/25/2005CA2556245A1 Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
08/25/2005CA2555848A1 Antibody targeting osteoclast-associated protein
08/25/2005CA2555017A1 Method and kit for identifying function of gene product and identifying binding substance
08/25/2005CA2554089A1 Albumin fusion proteins
08/24/2005EP1566442A2 Preparation and use of a human antibody gene bank (human antibody libraries)
08/24/2005EP1566440A2 Human Interleukin-11 Receptor
08/24/2005EP1566387A2 Genes involved in regulating angiogenesis, pharmaceutical preparations containing same and applications thereof
08/24/2005EP1565583A2 Hiv vaccine formulations
08/24/2005EP1565570A2 Diagnosis of sepsis or sirs using biomarker profiles
08/24/2005EP1565564A2 Modified antibodies stably produced in milk and methods of producing same
08/24/2005EP1565561A1 A method for marker-less integration of a sequence of interest into the genome of a cell
08/24/2005EP1565557A2 Mismatch endonucleases and methods of use
08/24/2005EP1565489A2 Novel raag10 cell surface target and a family of antibodies recognizing that target
08/24/2005EP1565487A2 Peptides binding the phosphatase 2a protein and polynucleotides encoding same
08/24/2005EP1565205A2 Interferon-alpha polypeptides and conjugates
08/24/2005EP1565199A2 Therapeutic polypeptides,nucleic acids encoding same, and methods of use
08/24/2005EP1238085B1 Bacillus thuringiensis toxin active against formicidae (ant)
08/24/2005EP1092036B1 Method for catalysing complex reactions of large molecules using enzymes which are bonded to a polymer support
08/24/2005EP1038014B1 VEGETABLE (GntI) SEQUENCES AND THE USE THEREOF TO OBTAIN PLANTS WITH A REDUCED OR LACK OF N-ACETYLGLUCOSAMINYLTRANSFERASE I (GnTI) ACTIVITY
08/24/2005EP0792370B1 Interleukin-1 beta converting enzyme like apoptosis protease-3 and 4
08/24/2005EP0684955B1 Nuclear matrix proteins
08/24/2005EP0662132B1 Self-assembling recombinant hpv16 papillomavirus capsid proteins
08/24/2005CN1659438A G-protein coupled receptor ligands and methods
08/24/2005CN1659437A Method for mapping and eliminating T-cell epitopes
08/24/2005CN1659283A Bacillus licheniformis mutant host cell
08/24/2005CN1659282A Bacillus licheniformis mutant host cell
08/24/2005CN1659276A Phospholipases, nucleic acids encoding them and methods for making and using them
08/24/2005CN1659274A Cytokine receptor
08/24/2005CN1659180A Novel recombinant anticoagulant proteins
08/24/2005CN1658906A Mycoplasma polypeptides
08/24/2005CN1658901A Methods for treating TWEAK-related conditions
1 ... 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 ... 1125